In addition, GLP-1R is highly expressed in the heart, and prominent in the therapeutics of T2D due to their efficacy in glycemia, safety, low risk of hypoglycemia and multilevel pathophysiological superiority [181] and benefits in cardiovascular disease reduction [182]. This evidence concerns the gene GLP1R and cardiovascular disorder.